S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.24 (-1.22%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.24 (-1.22%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.24 (-1.22%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.24 (-1.22%)
AAPL   172.54 (-2.01%)
MSFT   312.27 (-1.66%)
META   299.00 (-0.61%)
GOOGL   127.90 (-2.45%)
AMZN   127.44 (-2.92%)
TSLA   246.81 (-0.07%)
NVDA   421.20 (-0.24%)
NIO   8.49 (+1.68%)
BABA   86.08 (-1.31%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.51 (-0.56%)
MU   68.20 (-0.55%)
CGC   0.95 (+0.39%)
GE   109.99 (-1.55%)
DIS   80.52 (-0.60%)
AMC   8.17 (+0.37%)
PFE   32.87 (-0.33%)
PYPL   59.05 (+0.32%)
NFLX   382.43 (-0.62%)
NASDAQ:INCR

InterCure (INCR) Stock Forecast, Price & News

$1.57
-0.03 (-1.88%)
(As of 11:50 AM ET)
Compare
Today's Range
$1.55
▼
$1.57
50-Day Range
$1.39
▼
$1.72
52-Week Range
$1.39
▼
$5.56
Volume
13,509 shs
Average Volume
51,827 shs
Market Capitalization
N/A
P/E Ratio
12.08
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

InterCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
212.5% Upside
$5.00 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

See Top Rated MarketRank™ Stocks Here

INCR stock logo

About InterCure (NASDAQ:INCR) Stock

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

INCR Price History

INCR Stock News Headlines

September 1, 2023 | benzinga.com
Canndoc Reports Record Revenue Amid Cannabis Market Turmoil
August 22, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd up on Monday (INCR-U)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 19, 2023 | theglobeandmail.com
ul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)
August 3, 2023 | msn.com
InterCure: Leader In Israel's Growing Medical Cannabis Market
July 23, 2023 | theglobeandmail.com
Intercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)
July 10, 2023 | financialpost.com
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
May 16, 2023 | finanznachrichten.de
InterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
May 16, 2023 | msn.com
InterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The Details
May 15, 2023 | benzinga.com
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
April 27, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd down on Monday (INCR-U)
April 26, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd flat on Monday (INCR-U)
April 25, 2023 | finance.yahoo.com
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
April 24, 2023 | finance.yahoo.com
InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel
April 20, 2023 | finance.yahoo.com
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
April 19, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd flat on Friday (INCR-U)
April 15, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd down on Friday (INCR-U)
April 11, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd flat on Wednesday (INCR-U)
April 8, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd down on Wednesday (INCR-U)
April 3, 2023 | finance.yahoo.com
InterCure Reschedules 2022 Full Year Results Conference Call
April 3, 2023 | msn.com
InterCure Shares Soar On FY22 Record Revenue Of $108.3M
April 1, 2023 | theglobeandmail.com
Closing Bell: Intercure Ltd up on Thursday (INCR-U)
March 31, 2023 | finance.yahoo.com
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
March 30, 2023 | theglobeandmail.com
Intercure: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)
March 16, 2023 | money.usnews.com
Intercure Ltd
February 14, 2023 | msn.com
InterCure Sues Cann Pharmaceuticals To Recover Funds Following Failed Merger
See More Headlines
Receive INCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter.

INCR Company Calendar

Last Earnings
8/31/2023
Today
9/26/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INCR
CUSIP
N/A
CIK
1857030
Web
www.intercure.co
Phone
972774605012
Fax
N/A
Employees
370
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+212.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.13
Trailing P/E Ratio
12.31
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$13.36 million
Net Margins
4.28%
Pretax Margin
6.32%
Return on Equity
3.37%
Return on Assets
1.98%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
1.90
Quick Ratio
1.21

Sales & Book Value

Annual Sales
$115.83 million
Price / Sales
N/A
Cash Flow
$0.39 per share
Price / Cash Flow
4.12
Book Value
$3.64 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.03
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Alexander Rabinovitch (Age 52)
    CEO & Director
  • Mr. Amos Cohen (Age 44)
    Chief Financial Officer
  • Einat Zehavi
    VP of Sales
  • Mr. Rami Levy (Age 58)
    Chief Operating Officer of Canndoc
  • Mr. Omri Batzir
    Corp. Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













INCR Stock - Frequently Asked Questions

Should I buy or sell InterCure stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InterCure in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INCR shares.
View INCR analyst ratings or view top-rated stocks.

What is InterCure's stock price forecast for 2023?

1 brokerages have issued 12 month target prices for InterCure's stock. Their INCR share price forecasts range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price.
View analysts price targets for INCR or view top-rated stocks among Wall Street analysts.

How have INCR shares performed in 2023?

InterCure's stock was trading at $3.30 on January 1st, 2023. Since then, INCR stock has decreased by 51.5% and is now trading at $1.60.
View the best growth stocks for 2023 here.

Are investors shorting InterCure?

InterCure saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 34,900 shares, an increase of 156.6% from the August 15th total of 13,600 shares. Based on an average daily trading volume, of 46,500 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the shares of the company are short sold.
View InterCure's Short Interest.

When is InterCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our INCR earnings forecast.

How were InterCure's earnings last quarter?

InterCure Ltd. (NASDAQ:INCR) issued its quarterly earnings data on Thursday, August, 31st. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $28.08 million for the quarter. InterCure had a net margin of 4.28% and a trailing twelve-month return on equity of 3.37%.

What is InterCure's stock symbol?

InterCure trades on the NASDAQ under the ticker symbol "INCR."

Who are InterCure's major shareholders?

InterCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.20%), Cambria Investment Management L.P. (0.14%) and Citadel Advisors LLC (0.00%).

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InterCure's stock price today?

One share of INCR stock can currently be purchased for approximately $1.60.

How many employees does InterCure have?

The company employs 370 workers across the globe.

How can I contact InterCure?

The official website for the company is www.intercure.co. The company can be reached via phone at 972774605012.

This page (NASDAQ:INCR) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -